Clinical Trials



Mirati Therapeutics is developing drug candidates aimed at specific genetic mutations that we believe are drivers of cancer progression. Our clinical programs use genomic testing to identify the mutations in patient tumors that our drug candidates are specifically designed to target. This strategy allows us to identify the precise group of patients who may best respond to these investigational treatments.

To identify clinical trials that match your diagnosis, treatment history and location, call 1.844.356.0895 or use our online MIRATI STUDY LOCATOR

Mirati Clinical Trials

Non-Small Cell Lung Cancer

The targeting of defined genetic mutations that drive lung cancer progression has proven to be an effective treatment strategy in lung cancer. A number of cancer centers routinely analyze the DNA of lung cancer cells as part of the diagnosis and treatment strategy. This increase of genomic information has led to the discovery of more genetic mutations that may be drivers of lung cancer, which has opened doors to new approaches to treatment aimed specifically at those genetic mutations.

Mirati has three drug candidates in clinical trials.

INDICATIONS: Non-Small Cell Lung Cancer
DRUG CANDIDATE: Glesatinib (MGCD265)
DRIVER MUTATIONS: MET

We are currently evaluating the effects of glesatinib (MGCD265) as a treatment for non-small cell lung cancer patients whose tumors carry genetic alterations of MET including gene amplification of Exon14 deletion. Mirati and/or participating trial sites will analyze the molecular profile of the tumors of eligible patients to determine if selected mutations are present before enrolling in the clinical trial.


INDICATIONS: Non-Small Cell Lung Cancer
DRUG CANDIDATE: Sitravatinib (MGCD516)
DRIVER MUTATIONS: RET, CHR4q12, CBL, Trk, DDR

A Phase 1B expansion study evaluating the effects of sitravatinib (MGCD516) as a treatment for patients with non-small cell lung cancer whose tumors carry genetic alterations of RET, CHR4q12, CBL, Trk, and DDR. Participating trial sites will analyze the genetic sequence of the tumors of eligible patients to determine if those mutations are present before patients enroll in the clinical trial.


INDICATIONS: Non-Small Cell Lung Cancer
DRUG CANDIDATE: Glesatinib or sitravatinib in combination with nivolumab

An open label Phase 2 study evaluating the tolerability and clinical activity of glesatinib or sitravatinib in combination with nivolumab in patients with non-squamous NSCLC who have experienced progression of disease on or after treatment with checkpoint inhibitor therapy.

MORE INFORMATION IS AVAILABLE HERE – NCT02954991

 


INDICATIONS: Non-Small Cell Lung Cancer
DRUG CANDIDATE: Mocetinostat in combination with durvalumab

An open label Phase 1 / 2 study evaluating the tolerability and clinical activity of mocetinostat in combination with durvalumab in patients with Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer. Patients eligible for this study may have previously received treatment with a checkpoint inhibitor.

MORE INFORMATION IS AVAILABLE HERE – NCT02805660

 


Mirati is seeking collaborations with investigators and clinical sites interested in exploring program combinations and novel approaches to targeted cancer therapy. For more information, contact bd@mirati.com.

This information is not intended to replace the informed medical advice or medical treatments of a health care professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient or whether enrollment in a clinical trial is appropriate for a patient. If you have questions regarding appropriate treatment of your medical condition, you must consult a suitably qualified healthcare professional.